BridgeBio Pharma, Inc. Fair Value Adjustment of Warrants
BridgeBio Pharma, Inc. (BBIO) reported Fair Value Adjustment of Warrants of $0 for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2024-08-01
- BridgeBio Pharma, Inc. fair value adjustment of warrants for the quarter ending 2023-12-31 was -$1.04M, a 928.80% decline year-over-year.
- BridgeBio Pharma, Inc. fair value adjustment of warrants for the quarter ending 2023-09-30 was $274.00K, a 389.29% increase year-over-year.
- BridgeBio Pharma, Inc. fair value adjustment of warrants for the quarter ending 2023-06-30 was -$111.00K, a 120.63% decline year-over-year.
- BridgeBio Pharma, Inc. fair value adjustment of warrants for the quarter ending 2023-03-31 was -$111.00K, a 113.03% decline year-over-year.
- BridgeBio Pharma, Inc. fair value adjustment of warrants for fiscal 2023 was -$984.00K, a 162.64% decline from fiscal 2022.
- BridgeBio Pharma, Inc. fair value adjustment of warrants for fiscal 2022 was $1.57M, a 31.24% increase from fiscal 2021.
- BridgeBio Pharma, Inc. fair value adjustment of warrants for fiscal 2021 was $1.20M.
- BridgeBio Pharma, Inc. fair value adjustment of warrants for fiscal 2020 was -$3.34M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2023-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$762.00K derived: sum of 2 quarters · filed 2024-02-22 | -$873.00K derived: sum of 3 quarters · filed 2024-08-01 | -$984.00K 10-K · filed 2024-02-22 |
| 2023-09-30 | $274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $163.00K derived: sum of 2 quarters · filed 2024-08-01 | $52.00K 10-Q · filed 2023-11-02 | $177.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | -$111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$222.00K 10-Q · filed 2024-08-01 | -$97.00K derived: sum of 3 quarters · filed 2024-08-01 | -$41.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$111.00K 10-Q · filed 2023-05-04 | $14.00K derived: sum of 2 quarters · filed 2024-02-22 | $70.00K derived: sum of 3 quarters · filed 2024-02-22 | $608.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $181.00K derived: sum of 2 quarters · filed 2024-02-22 | $719.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.57M 10-K · filed 2024-02-22 |
| 2022-09-30 | $56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $594.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.45M 10-Q · filed 2023-11-02 | $2.18M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $538.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.39M 10-Q · filed 2023-08-03 | $2.13M derived: sum of 3 quarters · filed 2024-02-22 | |
| 2022-03-31 | $852.00K 10-Q · filed 2023-05-04 | $1.59M derived: sum of 2 quarters · filed 2024-02-22 | ||
| 2021-12-31 | $738.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.20M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | $459.00K 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | -$3.34M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |